JP2023519807A5 - - Google Patents

Info

Publication number
JP2023519807A5
JP2023519807A5 JP2022550848A JP2022550848A JP2023519807A5 JP 2023519807 A5 JP2023519807 A5 JP 2023519807A5 JP 2022550848 A JP2022550848 A JP 2022550848A JP 2022550848 A JP2022550848 A JP 2022550848A JP 2023519807 A5 JP2023519807 A5 JP 2023519807A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cancer
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022550848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519807A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/019667 external-priority patent/WO2021173832A1/en
Publication of JP2023519807A publication Critical patent/JP2023519807A/ja
Publication of JP2023519807A5 publication Critical patent/JP2023519807A5/ja
Pending legal-status Critical Current

Links

JP2022550848A 2020-02-25 2021-02-25 癌治療方法 Pending JP2023519807A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062981355P 2020-02-25 2020-02-25
US62/981,355 2020-02-25
US202063105104P 2020-10-23 2020-10-23
US63/105,104 2020-10-23
PCT/US2021/019667 WO2021173832A1 (en) 2020-02-25 2021-02-25 Cancer treatment methods

Publications (2)

Publication Number Publication Date
JP2023519807A JP2023519807A (ja) 2023-05-15
JP2023519807A5 true JP2023519807A5 (cg-RX-API-DMAC7.html) 2024-02-26

Family

ID=75143716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550848A Pending JP2023519807A (ja) 2020-02-25 2021-02-25 癌治療方法

Country Status (7)

Country Link
US (1) US20230165968A1 (cg-RX-API-DMAC7.html)
EP (1) EP4110403A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023519807A (cg-RX-API-DMAC7.html)
KR (1) KR20220145871A (cg-RX-API-DMAC7.html)
AU (1) AU2021226570A1 (cg-RX-API-DMAC7.html)
CA (1) CA3169117A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021173832A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2024130003A1 (en) 2022-12-15 2024-06-20 Bolt Biotherapeutics, Inc. Cancer combination treatment method
CA3221817A1 (en) * 2023-06-30 2025-06-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Combination therapies for the treatment of cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
US20070014795A1 (en) 2004-12-30 2007-01-18 Dhodapkar Madhav V Compositions and methods for enhanced dendritic cell maturation and function
WO2007038720A2 (en) * 2005-09-27 2007-04-05 Coley Pharmaceutical Gmbh Modulation of tlr-mediated immune responses using adaptor oligonucleotides
AU2006312148B2 (en) 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
WO2017087280A1 (en) * 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
AU2017249229A1 (en) * 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
BR112019000071A2 (pt) * 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
TW201834697A (zh) * 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體-藥物結合物之組合療法
US20210154316A1 (en) * 2018-05-17 2021-05-27 Bolt Biotherapeutics, Inc. Immunoconjugates
US20220226492A1 (en) * 2019-03-15 2022-07-21 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting HER2
EP3937984A1 (en) * 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20220152215A1 (en) * 2019-03-15 2022-05-19 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting CEA
WO2020190762A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Macromolecule-supported tlr agonists
US20220226491A1 (en) * 2019-03-15 2022-07-21 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting PD-L1

Similar Documents

Publication Publication Date Title
JP2026035673A (ja) 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療
JP2019519499A5 (cg-RX-API-DMAC7.html)
JP7769032B2 (ja) 抗体-薬物コンジュゲート投与による転移性脳腫瘍の治療
CN111629788A (zh) 用拮抗性抗-pd-1抗体治疗癌症的方法
KR20200130356A (ko) 항-조직 인자 항체-약물 접합체 및 암 치료에서의 그의 용도
US20230398229A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
JP2023025036A (ja) がんの処置のためのアベルマブの投与レジメン
TW202306588A (zh) 抗體-藥物結合物與免疫檢查點抑制劑組合用於治療泌尿上皮癌之用途
JP2025148452A5 (cg-RX-API-DMAC7.html)
JP2022502079A5 (cg-RX-API-DMAC7.html)
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
JP2024536383A5 (cg-RX-API-DMAC7.html)
WO2024183622A1 (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
JP2025508739A5 (cg-RX-API-DMAC7.html)
CN113574070B (zh) 用于治疗骨肉瘤的组合物和使用方法
JP2024538755A5 (cg-RX-API-DMAC7.html)
US20230061858A1 (en) Treatment with site specific her2 antibody-drug conjugates
WO2023227115A1 (en) A method of treating solid tumor
US20260130922A1 (en) Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
HK40109224A (en) Use of antibody-drug conjugate in combination with immune checkpoint inhibitor in treatment of urothelial cancer
TW202615102A (zh) 抗體藥物偶聯物用於治療癌症的方法
WO2025162211A1 (zh) 抗her2抗体药物偶联物治疗胃癌的用途
WO2024183623A1 (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
HK40123344A (en) A method of treating solid tumor
JP2024538573A5 (cg-RX-API-DMAC7.html)